ATRC Q1 2026 Earnings Call Summary

AtriCure Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $141.2 million, a 14.3% increase year-over-year (12.8% on a constant currency basis).
U.S. Revenue: $116.2 million, up 14.9% from Q1 2025.
Adjusted EBITDA: $17.1 million, nearly double from $8.8 million in Q1 2025.
Net Income: Approximately breakeven at $100,000, compared to a net loss of $6.7 million in Q1 2025.
Gross Margin: 77.4%, up 246 basis points year-over-year.
Operating Expenses: Increased by 10.3% to $108.8 million, driven by R&D and SG&A investments.

2. Strategic Updates and Business Highlights

Product Performance:
- Pain management segment grew 28% year-over-year, primarily from the cryoSPHERE MAX probe.
- Cardiac ablation revenue increased 15%, driven by the EnCompass clamp.
- Appendage management revenue grew 16%, with AtriClip FLEX-Mini contributing significantly.
Clinical Trials: The BoxX-NoAF trial is progressing well, with 300 patients enrolled, ahead of schedule for full enrollment expected by year-end.
Regulatory Approvals: Received CE Mark for AtriClip FLEX-Mini and PRO-Mini, with plans to launch in Europe later this year.

3. Forward Guidance and Outlook

Full Year 2026 Revenue Guidance: Reiterated at $600 million to $610 million, reflecting 12% to 14% growth over 2025.
Adjusted EBITDA Guidance: Expected to be between $80 million and $82 million.
Q2 Expectations: Anticipated mid-single-digit sequential growth, with continued strong performance in pain management and appendage management segments.

4. Bad News, Challenges, or Points of Concern

International Market Headwinds: Continued uncertainty in the U.K. and lower distributor sales in Asia are impacting international revenue growth.
Minimally Invasive Ablation Segment: Experienced a 25% decline in U.S. sales, indicating challenges in this area.
Increased Operating Expenses: Driven by accelerated R&D investments for clinical trials, which may pressure margins in the short term.

5. Notable Q&A Insights

PFA Integration: Progressing well with first-in-human trials in Australia and Europe; FDA submission expected later this year.
Pain Management Growth: Surgeons are increasingly adopting cryoSPHERE MAX, with 70% of accounts now using it.
BoxX-NoAF Trial Feedback: Positive anecdotal outcomes reported by clinicians, with expectations for data release potentially at AATS next year.
Competitive Landscape: AtriCure remains confident in maintaining market share despite new entrants, emphasizing the importance of innovation and clinical evidence.
Quality Metrics Impact: Anticipated quality metrics for Afib treatment in cardiac surgery expected to drive future adoption and growth.

Overall, AtriCure's Q1 2026 results reflect strong growth and operational momentum, despite facing challenges in international markets and specific product segments. The company remains focused on innovation and clinical advancements to support long-term growth.

ATRC — AtriCure, Inc.